BACKGROUND AND OBJECTIVES: Unlike other cancers, the Sentinel Lymph Node (SLN) procedure in bladder cancer requires special attention to the injection technique. The aim of this study was to assess feasibility and to optimize tracer injection technique for SLN mapping in bladder cancer patients using NIR fluorescence imaging. METHODS: Twenty patients with invasive bladder cancer scheduled for radical cystectomy were prospectively enrolled. Indocyanine green (ICG) bound to human serum albumin (complex ICG:HSA; 500 µM) was injected peritumourally to permit SLN mapping. ICG:HSA was first administrated serosally (n = 5), and subsequently mucosally by cystoscopic injection (n = 15). In the last cohort of 12 patients treated with cystoscopic injection, the bladder was kept filled with saline for at least 15 min. RESULTS: Fluorescent lymph nodes were observed only in the patient group with cystoscopic injection of ICG:HSA. Filling of the bladder post-injection was of added value to promote drainage of ICG:HSA to the lymph nodes, and in 11 of these 12 patients (92%) one or more NIR fluorescent lymph nodes were identified. CONCLUSIONS: The current study demonstrates proof-of-principle of using NIR fluorescence imaging for SLN identification in bladder cancer. Cystoscopic injection with distension of the bladder appears optimal for SLN mapping.
BACKGROUND AND OBJECTIVES: Unlike other cancers, the Sentinel Lymph Node (SLN) procedure in bladder cancer requires special attention to the injection technique. The aim of this study was to assess feasibility and to optimize tracer injection technique for SLN mapping in bladder cancerpatients using NIR fluorescence imaging. METHODS: Twenty patients with invasive bladder cancer scheduled for radical cystectomy were prospectively enrolled. Indocyanine green (ICG) bound to human serum albumin (complex ICG:HSA; 500 µM) was injected peritumourally to permit SLN mapping. ICG:HSA was first administrated serosally (n = 5), and subsequently mucosally by cystoscopic injection (n = 15). In the last cohort of 12 patients treated with cystoscopic injection, the bladder was kept filled with saline for at least 15 min. RESULTS: Fluorescent lymph nodes were observed only in the patient group with cystoscopic injection of ICG:HSA. Filling of the bladder post-injection was of added value to promote drainage of ICG:HSA to the lymph nodes, and in 11 of these 12 patients (92%) one or more NIR fluorescent lymph nodes were identified. CONCLUSIONS: The current study demonstrates proof-of-principle of using NIR fluorescence imaging for SLN identification in bladder cancer. Cystoscopic injection with distension of the bladder appears optimal for SLN mapping.
Authors: Boudewijn E Schaafsma; J Sven D Mieog; Merlijn Hutteman; Joost R van der Vorst; Peter J K Kuppen; Clemens W G M Löwik; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: J Surg Oncol Date: 2011-04-14 Impact factor: 3.454
Authors: Henk G van der Poel; Tessa Buckle; Oscar R Brouwer; Renato A Valdés Olmos; Fijs W B van Leeuwen Journal: Eur Urol Date: 2011-04-01 Impact factor: 20.096
Authors: Cristina Gazquez; Maria José Ribal; Mercedes Marín-Aguilera; Hany Kayed; Pedro Luís Fernández; Lourdes Mengual; Antonio Alcaraz Journal: BJU Int Date: 2012-03-15 Impact factor: 5.588
Authors: Martijn Hgm van der Pas; Sybren Meijer; Otto S Hoekstra; Ingid I Riphagen; Henrica C W de Vet; Dirk L Knol; Nicole C T van Grieken; Wilhelmus J H J Meijerink Journal: Lancet Oncol Date: 2011-05-04 Impact factor: 41.316
Authors: Matthias May; Edwin Herrmann; Christian Bolenz; Sabine Brookman-May; Arne Tiemann; Rudolf Moritz; Hans-Martin Fritsche; Maximilian Burger; Lutz Trojan; Maurice S Michel; Christian Wülfing; Stefan C Müller; Jörg Ellinger; Alexander Buchner; Christian G Stief; Derya Tilki; Wolf F Wieland; Christian Gilfrich; Thomas Höfner; Markus Hohenfellner; Axel Haferkamp; Jan Roigas; Mario Zacharias; Patrick J Bastian Journal: Ann Surg Oncol Date: 2011-01-19 Impact factor: 5.344
Authors: Floris P R Verbeek; Joost R van der Vorst; Boudewijn E Schaafsma; Rutger-Jan Swijnenburg; Katja N Gaarenstroom; Henk W Elzevier; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: J Urol Date: 2013-03-01 Impact factor: 7.450
Authors: Maria Triantafyllou; Urs E Studer; Frédéric D Birkhäuser; Achim Fleischmann; Lauren J Bains; Giuseppe Petralia; Andreas Christe; Johannes M Froehlich; Harriet C Thoeny Journal: Eur J Cancer Date: 2012-10-18 Impact factor: 9.162
Authors: Floris P R Verbeek; Joost R van der Vorst; Boudewijn E Schaafsma; Merlijn Hutteman; Bert A Bonsing; Fijs W B van Leeuwen; John V Frangioni; Cornelis J H van de Velde; Rutger-Jan Swijnenburg; Alexander L Vahrmeijer Journal: J Hepatobiliary Pancreat Sci Date: 2012-11 Impact factor: 7.027
Authors: Marcin Markuszewski; Magdalena Buszewska-Forajta; Małgorzata Artymowicz; Wojciech Połom; Marek Roslan; Michał Markuszewski Journal: Arch Med Sci Date: 2021-01-08 Impact factor: 3.707
Authors: William A Zammarrelli; Anoushka M Afonso; Vance Broach; Yukio Sonoda; Oliver Zivanovic; Jennifer J Mueller; Mario M Leitao; Amelia Chan; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2021-05-13 Impact factor: 5.304